Model-based Cost-effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York, and Texas.

Jo, Youngji; Shrestha, Sourya; Gomes, Isabella; Marks, Suzanne; Hill, Andrew; Asay, Garrett; Dowdy, David

Jo, Youngji; Shrestha, Sourya; Gomes, Isabella; Marks, Suzanne; Hill, Andrew; Asay, Garrett; Dowdy, David.

Afiliação

Jo Y; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Shrestha S; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Gomes I; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Marks S; Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Hill A; Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Asay G; Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Dowdy D; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Clin Infect Dis ; 73(9): e3476-e3482, 2021 11 02.

Article em En | MEDLINE | ID: mdl-32584968

Assuntos

Tuberculose Latente; California/epidemiologia; Análise Custo-Benefício; Florida/epidemiologia; Humanos; Tuberculose Latente/tratamento farmacológico; Tuberculose Latente/epidemiologia; New York; Texas/epidemiologia; Estados Unidos

Palavras-chave

United States; cost effectiveness; latent tuberculosis; targeting TB preventive therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose Latente Tipo de estudo: Health_economic_evaluation Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google